Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist at Mayo Clinic, suggests that medical providers can reduce patient ...

Johnson amp Johnson exceeded Wall Street expectations for fourth-quarter revenue and profit with robust sales of cancer ...

First, the liver cancer treatment 'TULBEGIO ... a boom in biosimilars is expected, so this year, even more domestically produced new drugs and pharmaceuticals are expected to receive FDA approval ...

Swiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for ...

Darzalex, which treats multiple myeloma, has become the first Johnson & Johnson drug to ever top $3 billion in quarterly ...

Indian biopharma company Biocon reported third-quarter revenue on Thursday that fell about 3% when compared with the ...

Johnson & Johnson surpasses expectations with robust fourth-quarter profits, backed by its acquisition of Intra-Cellular and ...

The cost of cancer may be higher than previously estimated, according to a recent report from the American Cancer Society.

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in ...

Now let’s return to the three factors that will influence biosimilar oncology drug uptake in Europe ... very closely at the evidence base for new cancer biosimilars reaching the market, and ...

which has already got a biosimilar to Roche’s Avastin (bevacizumab) cancer drug backed by the FDA. Amgen already has a biosimilar of AbbVie’s Humira (adalimumab) approved in the US ...

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS ...